E-GEOD-51083 - Global gene expression changes in patient-derived CML cell line K562 after short- and long-term BCR-ABL kinase inhibition
Released on 24 September 2013, last updated on 13 May 2014
K562 cells were treated with the BCR-ABL kinase inhibitor dasatinib over an extended period of time to determine how BCR-ABL inhibition affects BCR-ABL-dependent negative feedback and erythropoietin receptor (EPO-R) signaling. Specifically, what types of changes (upregulation versus downregulation) occur in both the negative and positive regulators of growth-factor receptor signaling. Total RNA was extracted from K562 cells treated with 0.2% DMSO for 24hrs or 100nM dasatinib for 4hrs, 8hrs, and 24hrs.
transcription profiling by array
Neil Shah <email@example.com>, Alma Burlingame, Barry S Taylor, Charles Craik, Cheryl Tajon, Elisabeth A Lasater, Jennifer Gajan, Juan Oses-Prieto, Neil P Shah, Young-wook Jun